| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
A fatal jump: not if, but when
|
Pope, Jessica
|
|
|
23 |
10 |
p. 1116
|
article
|
| 2 |
A holistic approach to HIV management
|
Ashley-Norman, Phoebe
|
|
|
23 |
10 |
p. 1115
|
article
|
| 3 |
Antibody neutralisation of emerging SARS-CoV-2 subvariants: EG.5.1 and XBC.1.6
|
Wang, Qian
|
|
|
23 |
10 |
p. e397-e398
|
article
|
| 4 |
Antiviral efficacy of the SARS-CoV-2 XBB breakthrough infection sera against omicron subvariants including EG.5
|
Kaku, Yu
|
|
|
23 |
10 |
p. e395-e396
|
article
|
| 5 |
A partner protection package for HIV cure-related trials involving analytical treatment interruptions
|
Dubé, Karine
|
|
|
23 |
10 |
p. e418-e430
|
article
|
| 6 |
A three-level model for therapeutic drug monitoring of antimicrobials at the site of infection
|
Brasier, Noé
|
|
|
23 |
10 |
p. e445-e453
|
article
|
| 7 |
Can we control dengue?
|
The Lancet Infectious Diseases,
|
|
|
23 |
10 |
p. 1095
|
article
|
| 8 |
Causal chemoprophylactic activity of cabamiquine against Plasmodium falciparum in a controlled human malaria infection: a randomised, double-blind, placebo-controlled study in the Netherlands
|
van der Plas, Johan L
|
|
|
23 |
10 |
p. 1164-1174
|
article
|
| 9 |
Clean Hospitals Day 2023 and the launch of an environmental-hygiene self-assessment tool
|
Peters, Alexandra
|
|
|
23 |
10 |
p. e390
|
article
|
| 10 |
Correction to Lancet Infect Dis 2023; 23: 983
|
|
|
|
23 |
10 |
p. e400
|
article
|
| 11 |
Correction to Lancet Infect Dis 2022; 22: 64–72
|
|
|
|
23 |
10 |
p. e400
|
article
|
| 12 |
Correction to Lancet Infect Dis 2022; 22: 1293–302
|
|
|
|
23 |
10 |
p. e400
|
article
|
| 13 |
Correction to Lancet Infect Dis 2023; published online Aug 3. https://doi.org/10.1016/S1473-3099(23)00344-4
|
|
|
|
23 |
10 |
p. e400
|
article
|
| 14 |
Correction to Lancet Infect Dis 2023; published online June 8. https://doi.org/10.1016/S1473-3099(23)00299-2
|
|
|
|
23 |
10 |
p. e400
|
article
|
| 15 |
COVID-19 pandemic: a catalyst for accelerating global action on patient safety
|
Grant, Rebecca
|
|
|
23 |
10 |
p. 1108-1110
|
article
|
| 16 |
Environment and infectious diseases
|
Burki, Talha
|
|
|
23 |
10 |
p. 1118
|
article
|
| 17 |
Exploring the potential benefits of mucosal COVID-19 vaccines: opportunities and challenges
|
Croda, Julio
|
|
|
23 |
10 |
p. 1099-1100
|
article
|
| 18 |
First treatment approved for molluscum contagiosum
|
Venkatesan, Priya
|
|
|
23 |
10 |
p. e402
|
article
|
| 19 |
Gerald Lee “Jerry” Mandell
|
Bagcchi, Sanjeet
|
|
|
23 |
10 |
p. 1113
|
article
|
| 20 |
Haemophilus influenzae is fighting back: is serotype a an emerging threat?
|
Wall, Emma C
|
|
|
23 |
10 |
p. 1106-1108
|
article
|
| 21 |
Inactivated Zika virus vaccine and the complexity of flavivirus antigenicity
|
Low, Jenny G
|
|
|
23 |
10 |
p. 1103-1105
|
article
|
| 22 |
Infectious diseases in Indigenous populations in North America: learning from the past to create a more equitable future
|
Lee, Naomi R
|
|
|
23 |
10 |
p. e431-e444
|
article
|
| 23 |
Infectious diseases surveillance update
|
Zwizwai, Ruth
|
|
|
23 |
10 |
p. e407
|
article
|
| 24 |
Iraq eliminates trachoma as a public health problem
|
Balakrishnan, Vijay Shankar
|
|
|
23 |
10 |
p. e404
|
article
|
| 25 |
Locally acquired malaria cases in the USA
|
Bagcchi, Sanjeet
|
|
|
23 |
10 |
p. e401
|
article
|
| 26 |
Mobile laboratory donations to African countries
|
Nakkazi, Esther
|
|
|
23 |
10 |
p. e403
|
article
|
| 27 |
Molecular-viability testing and antimicrobial resistance in sexually transmitted infections
|
Huston, Wilhelmina M
|
|
|
23 |
10 |
p. e399
|
article
|
| 28 |
Moving seasonal malaria chemoprevention out of its geographical isolation
|
Olotu, Ally
|
|
|
23 |
10 |
p. 1102-1103
|
article
|
| 29 |
Neena Valecha—stepping up malaria elimination efforts in southeast Asia
|
Kirby, Tony
|
|
|
23 |
10 |
p. 1114
|
article
|
| 30 |
Neutralisation sensitivity of SARS-CoV-2 lineages EG.5.1 and XBB.2.3
|
Zhang, Lu
|
|
|
23 |
10 |
p. e391-e392
|
article
|
| 31 |
Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial
|
Bramante, Carolyn T
|
|
|
23 |
10 |
p. 1119-1129
|
article
|
| 32 |
Pulmonary paragonimiasis in a child with chronic recurrent wet cough
|
Tsanglao, Wonashi R
|
|
|
23 |
10 |
p. e454
|
article
|
| 33 |
Research in brief
|
Devi, Sharmila
|
|
|
23 |
10 |
p. e408
|
article
|
| 34 |
Revisiting the minimum incubation period of Zaire ebolavirus
|
Kofman, Aaron D
|
|
|
23 |
10 |
p. 1111-1112
|
article
|
| 35 |
Safety and immunogenicity of a novel multivalent OspA-based vaccine candidate against Lyme borreliosis: a randomised, phase 1 study in healthy adults
|
Bézay, Nicole
|
|
|
23 |
10 |
p. 1186-1196
|
article
|
| 36 |
Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trial
|
Koren, Michael A
|
|
|
23 |
10 |
p. 1175-1185
|
article
|
| 37 |
Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial
|
Li, Jing-Xin
|
|
|
23 |
10 |
p. 1143-1152
|
article
|
| 38 |
Safety of COVID-19 booster dose: is the juice worth the squeeze?
|
Madhi, Shabir A
|
|
|
23 |
10 |
p. 1097-1099
|
article
|
| 39 |
Safety of monovalent and bivalent BNT162b2 mRNA COVID-19 vaccine boosters in at-risk populations in Israel: a large-scale, retrospective, self-controlled case series study
|
Yamin, Dan
|
|
|
23 |
10 |
p. 1130-1142
|
article
|
| 40 |
SARS-CoV-2-related mortality decrease in nursing home residents given multiple COVID-19 boosters
|
Blom, Kim
|
|
|
23 |
10 |
p. e393-e394
|
article
|
| 41 |
Scabies: the neglected tropical disease that is everywhere
|
Burki, Talha
|
|
|
23 |
10 |
p. e405-e406
|
article
|
| 42 |
Super-spreaders: a historical review
|
Teicher, Amir
|
|
|
23 |
10 |
p. e409-e417
|
article
|
| 43 |
Tafenoquine and artemisinin-based combination therapy for vivax malaria: end of the road or just the beginning?
|
Thriemer, Kamala
|
|
|
23 |
10 |
p. 1100-1102
|
article
|
| 44 |
Tafenoquine co-administered with dihydroartemisinin–piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study
|
Sutanto, Inge
|
|
|
23 |
10 |
p. 1153-1163
|
article
|
| 45 |
The birth of intensive care units
|
Conforti, Marco
|
|
|
23 |
10 |
p. 1117
|
article
|
| 46 |
The therapeutic validation of long COVID
|
Faust, Jeremy Samuel
|
|
|
23 |
10 |
p. 1096-1097
|
article
|
| 47 |
Trends in invasive Haemophilus influenzae serotype a disease in England from 2008–09 to 2021–22: a prospective national surveillance study
|
Bertran, Marta
|
|
|
23 |
10 |
p. 1197-1206
|
article
|
| 48 |
VLA15, a new global Lyme disease vaccine undergoes clinical trials
|
Hajdusek, Ondrej
|
|
|
23 |
10 |
p. 1105-1106
|
article
|
Journal description